SCHEMBL24847183

SCHEMBL24847183

CC1(C)OB(c2ccc(N3CCC(CO)CC3)cc2Cl)OC1(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 2/20 0.38
SYK P43405 1/20 0.36
WEE1 P30291 1/20 0.35
ADRB1 P08588 1/20 0.35
NOTUM Q6P988 1/20 0.34
BRD4 O60885 1/20 0.34
HTT P42858 2/20 0.33
TP53BP1 Q12888 1/20 0.33
L3MBTL3 Q96JM7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DPP4 P27487 1/20 0.33
AR P10275 1/20 0.33
MAPT P10636 1/20 0.33
MAPK1 P28482 1/20 0.33
DRD2 P14416 1/20 0.33
DRD1 P21728 1/20 0.33
DRD4 P21917 1/20 0.33
DRD5 P21918 1/20 0.33
DRD3 P35462 1/20 0.33
PTGES O14684 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30180207 1.00 SUV39H2 (0.38) SUV39H2SYKWEE1ADRB1NOTUM
SCHEMBL30180211 1.00 SUV39H2 (0.38) SUV39H2SYKWEE1ADRB1NOTUM
SCHEMBL26447710 0.87 MEN1 (0.35) SUV39H2BRD4PTGESRORC
SCHEMBL2053569 0.81 LIPG (0.41) RORC
SCHEMBL806747 0.80 MEN1 (0.42) ADRB1HTTL3MBTL1MAPTMAPK1
SCHEMBL24511910 0.79 MAPT (0.44) HTTL3MBTL1MAPTMAPK1DRD2
SCHEMBL789720 0.79 LGMN (0.44) HTTL3MBTL1MAPTMAPK1LMNA
SCHEMBL30180197 0.79 LIPG (0.40) SUV39H2BRD4RORC
SCHEMBL24846896 0.79 LIPG (0.40) SUV39H2BRD4RORC
SCHEMBL28978064 0.76 L3MBTL1 (0.44) SUV39H2SYKWEE1ADRB1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-06-05 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-04 US disclosed
WO-2023278759-A1 MK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230135894-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 SUV39H2 897/4885SYK 2840/4885WEE1 1632/4885
US-20250179075-A1 MK2 DEGRADERS AND USES THEREOF MKNK2, MKRN3, DUS2 SUV39H2 897/4885SYK 2840/4885WEE1 1632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.